跳转至内容
Merck
CN
所有图片(1)

主要文件

安全信息

Y0001047

Teicoplanin for identification

European Pharmacopoeia (EP) Reference Standard

别名:

Teicoplanin, Targocid, Teichomycin

登录查看公司和协议定价
所有图片(1)

About This Item

CAS号:
61036-62-2
UNSPSC代码:
41116107
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

teicoplanin

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

−20°C

SMILES字符串

Clc1c2ccc(c1)[C@H]([C@@H]4NC(=O)[C@H](NC(=O)[C@@H]8NC(=O)[C@H]9NC(=O)[C@H](NC(=O)[C@@H](c%13cc(c(cc%13)O)Oc%14cc9cc(c%14)O)[N+H3])Cc%10cc(c(cc%10)Oc%11c(c(cc8c%11)O2)O[C@@H]%12O[C@@H]([C@H]([C@@H]([C@H]%12NC(=O)CCCCCCCCC)O)O)CO)Cl)c5cc(c(cc5)O)c6c(cc(cc6O

InChI

1S/C88H97Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)94-68-74(113)71(110)58(32-101)129-87(68)132-78-55-26-40-27-56(78)126-52-18-14-38(24-47(52)90)77(131-86-67(92-34(2)103)73(112)70(109)57(31-100)128-86)69-84(121)98-66(85(122)123)45-29-42(105)30-54(127-88-76(115)75(114)72(111)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)99-69)96-83(120)65(40)97-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)95-64)20-35-11-17-51(125-55)46(89)19-35/h11-19,21-30,48,57-59,62-77,86-88,100-102,104-107,109-115H,3-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,108)(H,95,116)(H,96,120)(H,97,119)(H,98,121)(H,99,118)(H,122,123)/t48-,57-,58-,59-,62-,63-,64+,65-,66-,67-,68-,69+,70-,71-,72-,73-,74-,75+,76+,77-,86+,87+,88+/m1/s1

InChI key

BJNLLBUOHPVGFT-QRZIFLFXSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Teicoplanin for identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

Teicoplanin is a glycopeptide antibiotic produced by Actinoplanes teichomiceticus that is effective against Gram-positive bacteria resistant to β-lactam antibiotics. Its mechanism of action is through inhibition of bacterial cell wall biosynthesis.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Complex oxidation chemistry in the biosynthetic pathways to vancomycin/teicoplanin antibiotics.
Paul F Widboom et al.
Chembiochem : a European journal of chemical biology, 10(11), 1757-1764 (2009-06-18)
Hugo Paganini et al.
Medicina, 62 Suppl 2, 52-55 (2002-12-17)
Teicoplanin is a glycopeptide antibiotic with similar spectrum to vancomycin. Its long half-life permits administration in a single daily dose. The adverse effects of teicoplanin are less frequent than those of vancomycin. Rash and local intolerance are the most frequent.
Hyung-Moo Jung et al.
Applied microbiology and biotechnology, 84(3), 417-428 (2009-07-18)
The glycopeptide teicoplanin isolated from the fermentation broth of Actinoplanes teichomyceticus is used to treat serious Gram-positive bacterial infections that are resistant to other antibiotics, e.g. beta-lactams. The long time frame and progressively broader clinical use of teicoplanin has eventually
Claudia Pensotti et al.
Medicina, 62 Suppl 2, 40-47 (2002-12-17)
We retrospectively evaluated 89 episodes of bone and joint infections due to methicillin-resistant staphylococci: 56 chronic osteomyelitis (CO), 10 septic arthritis (SA) and 23 infections associated to arthroplasties (IAA). We analyzed the efficacy of Teicoplanin (T) in three times a
Francisco Nacinovich et al.
Medicina, 62 Suppl 2, 36-39 (2002-12-17)
Antibiotic prophylaxis has become a standard of care in all surgical categories, since its impact in reducing the incidence of post-operative infections has now been well established. Antibiotic prophylaxis should target expected pathogens. Glycopeptide-based regimens have been considered a choice
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门